Glucagon Analogue Peptide GLP-1 Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and glucose tolerance issues are inadequate, as existing therapies fail to effectively address the increasing global health problem of obesity, which is linked to various diseases such as cardiovascular disease, type 2 diabetes, and reduced life expectancy, with a strong need for efficacious treatment options.
Innovation Solution
Development of a glucagon analogue compound with specific peptide sequences that selectively target the GLP-1 receptor over the glucagon receptor, designed to inhibit food intake, reduce weight gain, and improve glucose tolerance, potentially used in combination with nucleic acids, expression vectors, and host cells for pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for obesity treatment, then current treatment protocols are maintained, but they fail to effectively address the increasing global health problem of obesity and related metabolic disorders
Solution Approach 1:
The patent modifies the glucagon peptide structure by substituting specific amino acid residues (e.g., position 2 with Aib or D-Ser, position 16 with Arg, His, Lys, or Glu) to create analogues with enhanced pharmacological properties. These parameter changes in the molecular structure improve both efficacy and adaptability to modern obesity treatment needs
2Measurement precision
If a glucagon analogue is designed to selectively target the GLP-1 receptor, then selectivity for GLP-1 receptor is improved, but potency for the glucagon receptor may be reduced
Solution Approach 1:
The patent applies local quality changes by making specific, targeted amino acid substitutions at particular positions in the glucagon sequence (e.g., position 2, 16, 17, 18, 20, 24, 27, 28) while leaving other regions unchanged. This localized modification strategy achieves enhanced GLP-1 receptor selectivity while preserving necessary glucagon receptor potency
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides material and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.